Disease · MONDO_0005607
Trials27
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
1 to 20 of 27
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02850978 | Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease | 1,335 | 2019-12-06 | Pulmonary Disease, Chronic Obstructive | TIOTROPIUM | Its record names the disease | ClinicalTrials.gov | |
| NCT01354938 | Outcome Study to Evaluate Klaricid XL® (Clarithromycin Modified Release) in Patients With Acute Exacerbation of Chronic Bronchitis | 220 | 2013-01-30 | Bronchitis | CLARITHROMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01509677 | Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease | Phase 3 | 158 | 2019-11-29 | COPD, Chronic Obstructive Pulmonary Disease | ROFLUMILAST | Its record names the disease | ClinicalTrials.gov |
| NCT04631016 | A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis | Phase 2 | 137 | 2025-02-27 | Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis | TOZORAKIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04441788 | A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB) | Phase 2 | 60 | 2022-12-20 | Chronic Bronchitis, Chronic Obstructive Pulmonary Disease | COFIRASERSEN | Its record names the disease | ClinicalTrials.gov |
| NCT01739790 | N-Acetylcysteine for Patients With COPD and Chronic Bronchitis | Not applicable | 51 | 2017-09-13 | COPD, Chronic Bronchitis | ACETYLCYSTEINE | Its record names the disease | ClinicalTrials.gov |
| NCT03085485 | The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor | Phase 2 | 40 | 2023-12-21 | Chronic Obstructive Pulmonary Disease, Chronic Bronchitis | IVACAFTOR | Its record names the disease | ClinicalTrials.gov |
| NCT01572948 | A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD) | Not applicable | 27 | 2015-07-31 | COPD | ROFLUMILAST | Its record names the disease | ClinicalTrials.gov |
| NCT01745848 | Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD | Phase 4 | 26 | 2017-08-29 | Chronic Obstructive Pulmonary Disease | ROFLUMILAST | Its record names the disease | ClinicalTrials.gov |
| NCT03073798 | The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis | Phase 4 | 12 | 2017-07-27 | COPD, Chronic Bronchitis, Emphysema | ROFLUMILAST | Its record names the disease | ClinicalTrials.gov |
| NCT03861390 | Woodsmoke Particulate + Prednisone | Phase 1/2 | 12 | 2024-05-23 | Airway Inflammation | PREDNISONE | Its record names the disease | ClinicalTrials.gov |
| NCT00870896 | The Effects of Tiotropium on the Cough Reflex in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Early phase 1 | 5 | 2014-09-15 | Chronic Obstructive Pulmonary Disease, Chronic Bronchitis | TIOTROPIUM | Its record names the disease | ClinicalTrials.gov |
| NCT03381573 | Long-term Observational Study of the Safety of Roflumilast | 135,856 | COPD | ROFLUMILAST | Its record names the disease | ClinicalTrials.gov | ||
| NCT04636801 | A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) | Phase 3 | 4,710 | Chronic Obstructive Pulmonary Disease | TRANIMILAST | Its record names the disease | ClinicalTrials.gov | |
| NCT04636814 | A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) | Phase 3 | 3,973 | Chronic Obstructive Pulmonary Disease | ROFLUMILAST, TRANIMILAST | Its record names the disease | ClinicalTrials.gov | |
| NCT00644449 | A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Acute Symptoms of Chronic Bronchitis | Phase 3 | 551 | Bronchitis, Chronic | AZITHROMYCIN, LEVOFLOXACIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00269932 | A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Cefuroxime Axetil in the Treatment of Adults With Persistent Bronchitis Experiencing Rapid Onset of Severe Worsening of Symptoms Caused by Bacteria | Phase 3 | 485 | Bronchitis, Chronic | CEFUROXIME AXETIL, LEVOFLOXACIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00338507 | Phase 2 Study - Erdosteine in Patients With CB/COPD | Phase 2 | 400 | Chronic Bronchitis, Chronic Obstructive Pulmonary Disease | ERDOSTEINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00257140 | A Study of the Safety and Effectiveness of Levofloxacin Compared With Cefaclor in the Treatment of Adults With Chronic Bronchitis Experiencing Rapid Onset of Worsening of Symptoms Caused by Bacteria | Phase 2/3 | 367 | Bronchitis, Bronchitis, Chronic | CEFACLOR, LEVOFLOXACIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02157571 | A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Exacerbations of Chronic Bronchitis With Levofloxacin Hydrochloride Tablet as Active Control | Phase 3 | 360 | Acute Exacerbations of Chronic Bronchitis | PRULIFLOXACIN | Open Targets' reading of its record | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005607/trials